Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States (Seneshock)

Circulatory shocks (CS) are life-threatening, acute organ dysfunction. Advances in critical care medicine have decreased early hospital mortality, increasing the number of surviving patients. Regrettably, these survivors are at increased risk of new infections but also of cardiovascular disease.

The investigators hypothesize that CS with multi-organ dysfunction is associated with premature senescence of endothelial cells and immune cells and promotes endothelial thrombogenicity and immunosenescence leading to cardiovascular disease and secondary infections.

The aim of this work is therefore to evaluate the contribution of endothelial and leucocytes senescence to the occurrence of secondary events (infectious and cardiovascular) in patients with a CS. It will provide a better understanding of the pathogenesis of cardiovascular and immune diseases following a CS, likely to guide new management strategies to prevent their occurrence.

Study Overview

• Status: Recruiting
• Conditions: Cardiovascular Diseases; Shock; Infection
• Intervention / Treatment: Biological: Biological samples will be done to evaluate the endothelial and leukocyte senescence.

• Study Type: Observational
• Enrollment (Estimated): 520

Contacts and Locations

• Study Contact: Name: Morgane CLERC; Phone Number: +33 03 88 11 68 55; Email: morgane.clerc@chru-strasbourg.fr
• Study Contact Backup: Name: Madoé JULIANS; Phone Number: +33 03 88 11 61 86; Email: madoe.julians@chru-strasbourg.fr

Study Locations

• France
  • Strasbourg, France, 67091
    • Recruiting
    • Hôpitaux Universitaires de Strasbourg - Service de Réanimation médicale du NHC
    • Contact: Ferhat MEZIANI
    • Contact: Ferhat MEZIANI; Phone Number: +33 03 69 55 10 24; Email: ferhat.meziani@chru-strasbourg.fr
    • Contact: Hamid MERDJI; Phone Number: +33 03 69 55 11 23; Email: hamid.merdji@chru-strasbourg.fr
    • Contact: Julie HELMS
    • Contact: Hamid MERDJI
    • Contact: Laure STIEL
    • Contact: Xavier DELABRANCHE
    • Contact: Christine KUMMERLEN
    • Contact: Hassène RAHMANI
    • Contact: Alexandra MONNIER
    • Contact: Yannick RABOUEL
    • Contact: Raphaël CLERE-JEHL
    • Contact: Dominique STEPHAN
    • Contact: Sébastien GAERTNER
    • Contact: Catherine MUTTER

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

All patients admitted in the intensive care unit of the "Nouvel Hôpital Civil de Strasbourg" for a circulatory shock will be included.

Healthy volunteer will be included in our Clinical Investigation Center of the "Hôpitaux Universitaires de Strasbourg"

Description

Inclusion criteria:

• Circulatory shock
• patient with health care insurance

Exclusion criteria:

• Patients' refusal to participate in clinical research
• Pregnant woman
• Breastfeeding woman
• A patient with a protective order

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with circulatory shock; 500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype	Biological: Biological samples will be done to evaluate the endothelial and leukocyte senescence.; Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
Healthy volunteers; 20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype.	Biological: Biological samples will be done to evaluate the endothelial and leukocyte senescence.; Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The main criterion will be the acquisition of a senescent phenotype concerning leukocytes and endothelial cells.	Biological samples will be done to evaluate the endothelial and leukocyte senescence.	1 year

Secondary Outcome Measures

Outcome Measure	Time Frame
Incidence of cardiovascular events and secondary infection in hospitalized patients in intensive care unit for circulatory shock states	5 years

Collaborators and Investigators

• Sponsor: University Hospital, Strasbourg, France
• Investigators: Principal Investigator: Ferhat MEZIANI, Hopitaux universitaires de Strasbourg

Study record dates

Study Major Dates

• Study Start (Actual): January 7, 2019
• Primary Completion (Estimated): February 1, 2028
• Study Completion (Estimated): March 1, 2028

Study Registration Dates

• First Submitted: May 17, 2018
• First Submitted That Met QC Criteria: June 5, 2018
• First Posted (Actual): June 18, 2018

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 5, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Infection; Shock; Cardiovascular Diseases
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Shock
• Other Study ID Numbers: 7031

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No